NCT00303316View on ClinicalTrials.gov

Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

458

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

September 30, 2007

Conditions
DiphtheriaTetanusPertussisPoliomyelitisHepatitis B
Interventions
BIOLOGICAL

DTaP-IPV//PRP~T combined vaccine

0.5 mL, Intramuscular

BIOLOGICAL

DTaP-IPV//PRP~T combined vaccine

0.5 mL, Intramuscular

Trial Locations (1)

5000

Córdoba

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00303316 - Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants | Biotech Hunter | Biotech Hunter